## **CURRICULUM VITAE**

Name: SUN H. KIM, M.D., M.S.

02/2018

present

03/01/2018-

Stanford, CA

Stanford, CA

Stanford University School of Medicine

**Position:** Associate Professor in University Medical Line

Department of Medicine

Division of Endocrinology, Metabolism, and Gerontology

Stanford University School of Medicine

EDUCATION			
09/1989-	Stanford University	B.A. honors	Psychology
06/1993	Stanford, CA	distinction	
09/1994-	University of California, San Diego	M.D.	Medicine
06/1998	La Jolla, CA		
07/1998-	University of Texas, Southwestern	Intern	Internal Medicine
06/1999	Dallas, TX		
07/1999-	University of Texas, Southwestern	Resident	Internal Medicine
06/2001	Dallas, TX		
07/2003-	Stanford University School of Medicine	Fellow	Endocrinology
06/2007	Stanford, CA		
09/2006-	Stanford University School of Medicine	M.S.	Epidemiology
06/2007	Stanford, CA		
<b>EMPLOYMENT</b>			
07/1993-	AmeriCorps, Nevada Self-Employment Trust		Volunteer
06/1994	Reno, NV		
07/2001-	Kaiser Permanente		Staff Physician
06/2003	Richmond, CA		
07/2007-	Stanford University School of Medicine		Instructor
05/2008	Stanford, CA		
06/2008-	Stanford University School of Medicine		Assistant Professor

Page 1 of 14 Last updated 12/14/2021

in University Medical

**Associate Professor** 

in University Medical

Line

Line

**HONORS and AWARDS** 

1996 Lange Medical Publications Award

Granted to the top second-year medical student based on scholastic achievement

and leadership

University of California, San Diego, School of Medicine, La Jolla, CA

1998 American Medical Women's Association Glasgow Memorial Achievement Award

Granted to the top female medical graduate based on scholastic achievement

and public service

University of California, San Diego, School of Medicine, La Jolla, CA

2003 American Heart Association Postdoctoral Fellowship

**American Heart Association** 

Dallas, TX

2003-2006 National Research Service Award

National Institute of Alcohol and Abuse

Bethesda, MD

2004 First Place Abstract

World Congress on the Insulin Resistance Syndrome

Los Angeles, CA

2011 Travel Award

Selected to attend the Adipogenic and Metabolic Effects of Antipsychotic Drugs Conference sponsored by the University of Alabama at Birmingham Nutrition

**Obesity Research Center** 

Funded by National Institute of Mental Health

Elizabeth, NJ

#### **CERTIFICATION AND LICENSURE**

2001 Medical Board of California (A75251)2001 American Board of Internal Medicine

2006, 2016 American Board of Internal Medicine, Endocrinology

2007 Drug Enforcement Agency (BK7116456)2007 National Provider Identifier (1083894844)

## **UNIVERSITY PROFESSIONAL ACTIVITIES**

Clinical

2007-present Attending Physician, Stanford Endocrinology and Diabetes Consult Service, 8 weeks 2007-present Attending Physician, Stanford Endocrinology Ambulatory Clinic, 2.5 days weekly

2010-present Faculty, Stanford Recurrent Pregnancy Loss Program

<u>Administrative</u>

2007 Freshman Adviser, Stanford University2009-present Interviewer, Stanford Medical School

2010-present Interviewer, Stanford Internal Medicine Residency Program

2011-2012 Member, Search Committee, Minimally Invasive and Bariatric Surgery,

Stanford University School of Medicine

2013-2014	Member, Search Committee, Cardiovascular Medicine, Stanford University School
	of Medicine
2019-present	Chair, Search Committee, Endocrinology, Stanford University School of Medicine
2021-2022	Member, Search Committee, Pediatric Endocrinology, Stanford University School
	of Medicine

PROFESSIONAL MI	EMBERSHIPS AND ACTIVITIES
<u>Membership</u>	
2008-present	Member, American Diabetes Association
2017-present	Member, Endocrine Society
<u>Activities</u>	
2012-2016	Member, Scientific and Medical Programs Oversight Committee of the American Diabetes Association (ADA)
2011-2013	Member, Data and Safety Monitoring Board, "Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy after Heart Transplantation" (PI: K. Khush).
2013-2020	Member, D2d study, Safety and Outcome Subcommittee
2015-2017	Member, Data and Safety Monitoring Board, "Qsymia for Binge Eating Disorder" (PI: D. Safer).
2015-2016	Member, ADA's Scientific Sessions Clinical Therapeutics/New Technologies Subcommittee
2018-present	Co-leader, Stanford Diabetes Research Center, Metabolism and Signaling Affinity Group
2019-present	Director, Type 2 Diabetes, Center for Asian Health Research and Education
2019-present	Member, Medical Monitoring Committee, EndoBarrier
C 1 - 1 - D ( 1	and B. Mariera

Service to Profess	sional Publications
2021-present	Editorial Board Member, Journal of Asian Health
2022	Associate Editor, Frontiers in Endocrinology, Clinical Diabetes
	Reviewer, Archives of Internal Medicine
	Reviewer, Annals of Internal Medicine

Reviewer, Diabetes Reviewer, Diabetes Care Reviewer, Diabetic Medicine Reviewer, Diabetologia

Reviewer, British Medical Journal

Reviewer, Journal of the American College of Cardiology

Reviewer, Journal of American Medical Association

Reviewer, Journal of Clinical Endocrinology and Metabolism

Reviewer, Journal of Clinical Psychiatry

Reviewer, Journal of Psychiatry and Neuroscience Reviewer, New England Journal of Medicine

Reviewer, Nutrition, Metabolism and Cardiovascular Diseases

Reviewer, Obesity Reviewer, PLOS ONE

## Service as Grant/Abstract Reviewer

2009 Ad Hoc Reviewer, National Institute of Diabetes and Digestive and Kidney Diseases

2015-present Reviewer, Department of Defense Grants

2015-present Reviewer, American Diabetes Association Abstracts

2018 Ad Hoc Reviewer, Wellcome Trust
 2019-present Chair, Department of Defense Grants
 2022- Reviewer, Endocrine Society Abstracts

## **TEACHING AND MENTORING**

## Formal Teaching

2007-present Lecturer, Human Health and Disease Course

Stanford University School of Medicine, Stanford, CA

2007-present Discussion Group Leader, Endocrinology Lab

Stanford University School of Medicine, Stanford, CA

2010 Faculty, Intensive Course in Clinical Research: Study Design and Performance

Stanford University School of Medicine, Stanford, CA

2011 Lecturer, Obesity in America Course

Stanford University School of Medicine, Stanford, CA

## **Informal Teaching**

2007-present	Lecturer, Stanford Endocrinology Fellowship lecture series
2007-present	Lecturer, Stanford House Staff noon lecture series
2014-present	Course Director, Stanford Endocrinology Journal Club

### Mentoring

ivientoring	
2010	Barry Johns
	Received Dean's Award. Publication #18.
2010-2011	Marilyn Tan, Internal Medicine Resident
2011-2012	Janet Leung, Internal Medicine Resident
2010-2013	Shubha Bhat, Medical Student
	Received MedScholars Award. Publications #17,20.
2012-2014	Jonathan Kort, OB/GYN Resident
	Received first prize oral presentation at the Pacific Coast Reproductive Society 61st
	Annual Meeting, 2013. Publication #24.
2013-2015	Ryan Siebert, Internal Medicine Resident. Publication #30.
2013-2016	Ioanna Comstock, REI Fellow. Publication #31, book chapter.
2014-2015	Mee Kim, Visiting Scholar from S. Korea. Publications #34, 38.

2015-2016	Chanhee Jung, Visiting Scholar from S. Korea. Publications #40, 41.
2016-2019	Yan Hang, Postdoctoral fellow, Developmental Biology
2016-present	Jinnie Rhee, Instructor, Nephrology. Publication #50
2017-2020	Julia Chang, Internal Medicine Resident. Publication #51
2018-2020	Seong Hwan Kim, Juri Park, Visiting Scholars from S. Korea. Publications #46 #54
2019-2020	Clara Nachmanoff, Undergraduate at Wesleyan University. Publication #53
2022-2023	Hayley Galitzer, Internal Medicine Resident.
2022-2023	Linus Amarikwa, Medical Student, UC Riverside.
2023-	Angela Nguyen, Stanford undergraduate. Received the Stanford VPUE grant.
2023-	Angela Nguyen, Stanford undergraduate. Received the Stanford VPUE grant.

# **COMMUNITY SERVICE**

2010	Speaker, Recurrent Pregnancy Loss Community Seminar
2011	Arrillaga Alumni Center, Stanford, CA Speaker, Endocrinology Update for Primary Care Practitioners
	Continuing Medical Education course Li Ka Shing Center, Stanford, CA
2011	Speaker, Obesity in America
	Continuing Medical Education course
	Arrillaga Alumni Center, Stanford, CA
2012	Speaker, Women's Health Forum
	Li Ka Shing Center, Stanford, CA
2013	Panelist, Diabetes Day
	Hewlett Packard, Palo Alto, CA
2014	Speaker, World Diabetes Day
	Qualcomm, San Jose, CA
2021	Speaker, Health Matters
	Virtual
	Speaker, Stanford Health Library
	Virtual
2022	Speaker, Liver Education Awareness Program
	Virtual
	Speaker, Center for Asian Health Research and Education
	Virtual
	Speaker, GoodRx
	Virtual

# **GRANTS AND CONTRACT AWARDS**

<u>Present</u>

09/2020-08/2024 Funder: NIH/R01

Title: Stratification of Non-Alcoholic Fatty Liver Disease Using the SAFE Score

Role: Co-investigator

01/2022-01/2024 Funder: Abbot

Title: Franklin Pilot Study Role: Co-investigator

12/2021-12/2023 Funder: Fractyl Laboratories

Title: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin therapy

Role: Co-investigator

09/2016-05/2023 Funder: NIH/R01

Title: Insulin Resistance and Accelerated Cognitive Aging

Role: Co-Investigator (PI:Rasgon)

<u>Past</u>		
2021-2022	Funder:	Stanford University's Innovative Medicines Accelerator
	Title:	Feasibility of empagliflozin in managing diuretic-resistant ascites in
		patients with cirrhosis
	Role:	Co-investigator
2017-2021	Funder:	Astra Zeneca
	Title:	A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and
		Cardiovascular Mortality in Patients with Chronic Kidney Disease
	Role:	Co-Investigator
2018-2020	Funder:	•
	Title:	6 6
2013-2020	Role:	PI
	Funder:	NIH/U01
	Title:	Vitamin D to prevent type 2 diabetes (D2d study)
2045 2040	5.1	Site PI
2015-2019	Role:	Janssen
		CREDENCE (Canagliflozin and Renal Events in Diabetes with Established
		Nephropathy Clinical Evaluation)
2011 2016	F	Site PI
2011-2016	Funder: Title:	NIH/U01 HL108647 Sleep apnea, Type 2 diabetes, and CVD: a cluster related to insulin
	nue.	resistance
	Role:	Co-Investigator (PI: Reaven)
2014-2015	Funder:	GI Dynamics
2014-2013	Title:	ENDO Trial (EndoBarrier)
	Role:	Co-Investigator (PI: McLaughlin)
2012-2015	Funder:	ADA
2012 2013	Title:	Effects of liraglutide on hippocampal structure and function in aging
		adults with prediabetes
	Role:	Co-Investigator (PI: Rasgon)
2010-2013	Funder:	NIH/R01 DK088136
	Title:	Beneficial effects of salicylates: insulin action, secretion, and clearance
	Role:	Co-Investigator (PI: Reaven)
2010-2013	Funder:	ADA
	Title:	Addition of the long-acting glucagon-like peptide-1, liraglutide, to a

calorie-restricted diet augments weight loss, and decreases risk of type 2

diabetes and cardiovascular disease in older, overweight/obese

Role: individuals

Co-Investigator (PI: Reaven)

2007-2012 Funder: NIMH/ K23 MH079114

Title: Olanzapine's Effect on Pancreatic β-cell Function in Schizophrenia

Role: PI

2010-2011 Funder: Clinical Translational Science Award Seed Grant

Title: Improving Metabolic Health in Patients with Severe Mental Illness

Role: PI

2008-2011 Funder: JDRF

Title: Biomarkers of β-cell Function and Proliferation

Role: Co-Investigator (Kim, Seung)

2003-2006 Funder: NIH/ F32 AA014470

Title: Alcohol Intake on Insulin Sensitivity and Heart Disease

Role: PI

## **PUBLICATIONS**

# <u>Peer-reviewed Journal Articles (Original Research)</u>

- KIM SH, Morton DJ, Barrett-Connor EL. Carbonated beverage consumption and bone mineral density among older women: The Rancho Bernardo Study. *American Journal of Public Health* 87:276-279, 1997.
- 2. **KIM SH**, Abbasi F, Reaven GM. Impact of Degree of Obesity on Surrogate Estimates of Insulin Resistance. *Diabetes Care* 27:1998-2002, 2004.
- 3. **Kim SH**, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, Reaven GM. Rosiglitazone Reduces Glucose-Stimulated Insulin Secretion Rate and Increases Insulin Clearance in Nondiabetic, Insulin Resistant Individuals. *Diabetes* 54:2447-2452, 2005.
- 4. **Kim SH**, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association Classification of Impaired Fasting Glucose (IFG): Impact on Prevalence of IFG, Coronary Heart Disease Risk Factors, and Coronary Heart Disease in a Community-Based Medical Practice. *Journal of the American College of Cardiology* 48:293-297, 2006.
- Farin HM, Abbasi F, Kim SH, Lamendola C, McLaughlin T, Reaven GM. The Relationship between Insulin Resistance and Dyslipidemia in Cigarette Smokers. *Diabetes, Obesity, and Metabolism* 9:65-9, 2007.
- 6. **Kim SH**, Ivanova O, Abbasi F, Lamendola C, Reaven GM, Glick I. Metabolic Impact of Switching Antipsychotic Therapy to Aripiprazole after Weight Gain: A Pilot Study. *Journal of Clinical Psychopharmacology* 27:365-8, 2007.
- 7. Sung KC, **Kim SH** (shared 1<sup>st</sup> author), Reaven GM. Relationship among Alcohol, Body Weight, and Cardiovascular Risk Factors in 27,030 Korean Men. *Diabetes Care* 30:2690-4, 2007.
- 8. **Kim SH**, Reaven GM. Isolated Impaired Fasting Glucose and Peripheral Insulin Sensitivity: Not a Simple Relationship. *Diabetes Care* 31:347-352, 2008.
- 9. **Kim SH**, Reaven GM. Insulin Resistance and Hyperinsulinemia: You Can't Have One without the Other. *Diabetes Care* 31:1433-8, 2008.

- 10. **Kim SH**, Abbasi F, Lamendola C, Reaven GM. Effect of Moderate Alcohol Consumption on Insulin Sensitivity in Insulin Resistant, Nondiabetic individuals. *Metabolism* 58:387-92, 2009.
- 11. **Kim SH,** Liu TC, Abbasi F, Lamendola C, Morton JM, Reaven GM, McLaughlin TL. Plasma Glucose and Insulin Regulation is Abnormal Following Gastric Bypass Surgery with or without Neuroglycopenia. *Obesity Surgery* 19:387-92, 2009.
- 12. **Kim SH**, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S. Relationship between Body Mass Index and Insulin Resistance in Patients Treated with Second Generation Antipsychotic Agents. *Journal of Psychiatric Research* 44:493-8, 2010.
- 13. Sung KC, Reaven GM, **Kim SH**. Utility of HOMA-β in Predicting Diabetes in 12,924 Healthy Koreans. *Diabetes Care* 33:200-2, 2010.
- 14. **KIM SH**, Abbasi F, Lamendola C, Reaven GM, McLaughlin TL. Glucose-stimulated Insulin Secretion in Gastric Bypass Patients with Hypoglycemic Syndrome: No evidence for inappropriate pancreatic β-cell function. *Obesity Surgery* 20:1110-6, 2010.
- 15. **Kim SH**, Reaven GM, Lindley S. Relationship between Insulin Resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications. *International Clinical Psychopharmacology* 26:43-7, 2011.
- 16. Sung KC, **Kim SH**. Interrelationship between Fatty Liver and Insulin Resistance in the Development of Type 2 Diabetes. *J Clinical Endocrinology and Metabolism* 96:1093-7, 2011.
- 17. Bhat S, Abbasi F, Blasey C, Reaven G, **Kim SH**. Plasma Glucose and Insulin Responses to Mixed-meals: Impaired Fasting Glucose Re-visited. *Diabetes and Vascular Disease Research* 8: 271-275, 2011.
- 18. Johns BR, Pao AC, **Kim SH**. Metabolic syndrome, Insulin Resistance, and Kidney Function in Nondiabetic Individuals. *Nephrology Dialysis Transplantation* 27:1410-5, 2012.
- 19. Sung KC, Choi JH, Gwon HC, Choi SH, Kim BS, **Kim SH**. Relationship between Insulin Resistance and Coronary Artery Calcium in Young Men and Women. *PLOS One* 8:e53316, 2013.
- 20. Bhat S, Abbasi F, Blasey C, Reaven G, **Kim SH**. Beyond Fasting Glucose: the Association between Coronary Heart Disease Risk and Postprandial Glucose, Postprandial Insulin and Insulin Resistance in Healthy, Nondiabetic Adults. *Metabolism* 62:1223-6, 2013.
- 21. **Kim SH**, Abbasi F, Lamendola C, Liu A, Ariel D, P Schaaf, Grove K, Tomasso V, H Ochoa, Y Liu, Y-I Chen, G Reaven. Benefits of Liraglutide Treatment in Overweight/Obese, Older Individuals with Prediabetes. *Diabetes Care* 36:3276-82, 2013.
- 22. **Kim SH**, Reaven G. Sex Differences in Insulin Resistance and Cardiovascular Disease Risk. *J Clinical Endocrinology and Metabolism*, 98:E1716-21, 2013.
- 23. **Kim SH**, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G. Pancreatic Beta Cell Function following Liraglutide-augmented Weight Loss in Individuals with Prediabetes: Analysis of a Randomised, Placebo-controlled study. *Diabetalogia* 57:455-62, 2013.
- 24. Kort J, Winget C, **Kim SH**,\* Lathi R. A Retrospective Cohort Study to Evaluate the Impact of Meaningful Weight Loss on Fertility Outcomes in an Overweight Population with Infertility. *Fertility and Sterility* 101:1400-3, 2014. \*Participated with conception and design of study, interpretation of data, and critical revision of manuscript.

- 25. Sung KC, Ryu S, Chang Y, Byrne CD, **Kim SH**. C-reactive Protein and Risk of Cardiovascular and All-Cause Mortality in 268,803 East Asians. *European Heart Journal* 35:1809-16, 2014.
- Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H, Reaven G. Effect of Salsalate on Insulin Action, Secretion, and Clearance in Nondiabetic, Insulin-Resistant Individuals: A Randomized, Placebo-Controlled Study. *Diabetes Care* 37:1944-50, 2014.
- 27. Sung KC, Reaven G, **Kim SH.** Ability of the Plasma Concentration Ratio of Triglyceride/high-density lipoprotein Cholesterol to Identify Increased Cardio-metabolic Risk in an East Asian Population. *Diabetes Research and Clinical Practice* 105: 96-101, 2014.
- 28. Ariel D, **Kim SH,\*** Abbasi F, Lamendola C, Liu A, Reaven G. Effect of Liraglutide Administration and a Calorie-restricted Diet on Lipoprotein Profile in Overweight/obese Persons without Diabetes. *Nutrition Metabolism and Cardiovascular Disease* 24:1317-22, 2014. \*Participated with conception and design of study, acquisition and interpretation of data, and critical revision of manuscript.
- 29. Liu A, Cardell J, Ariel D, Lamendola C, Abbasi F, **Kim SH**,\* Holmes TH, Tomasso V, Mojaddidi H, Grove K, Kushida CA, Reaven G. Abnormalities of Lipoprotein Concentrations in Obstructive Sleep Apnea are Related to Insulin Resistance. *Sleep* 38:793-9, 2015. \*Participated in the acquisition of data and revision of manuscript.
- 30. Siebert R, Abbasi F, Hantash F, Caulfield M, Reaven G, **Kim SH**. Relationship between Insulin Resistance and Amino Acids in Women and Men. *Physiological Reports* 3: e12392, 2015.
- 31. Comstock I, **Kim SH,\*** Behr B, Lathi R. Increased Body Mass Index Negatively Impacts Blastocyst Formation Rate in Normal Responders Undergoing In Vitro Fertilization. *Journal of Assisted Reproduction and Genetics* 32:1299-304, 2015. \*Participated in the interpretation of data and critical revision of the manuscript.
- 32. Liu A, Lamendola C, Ariel D, Abbasi F, **Kim SH**, Cardell J, Tomasso V, Xu S, Patel S, Mojaddidi H, Grove K, Kushida CA, Reaven GM. Usefulness of fetuin-A to Predict Risk for Cardiovascular Disease among Patients with Obstructive Sleep Apnea. *American Journal of Cardiology* 116:219-24, 2015. \*Participated in the acquisition of data and revision of manuscript.
- 33. Ariel D, **Kim SH,\*** Liu A, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven GM. Salsalate-induced Changes in Lipid, Lipoprotein, and Apoprotein Concentrations in Overweight or Obese, Insulinresistant, Nondiabetic Individuals. *Journal of Clinical Lipidology* 9:658-63, 2015. \*Participated with conception and design of study, acquisition and interpretation of data, and critical revision of manuscript.
- 34. Kim MK, Reaven GM, **Kim SH**. Hyperinsulinemia in Individuals with Obesity: Role of Insulin Clearance. *Obesity* 23:2430-4, 2015.
- 35. Liu A, Ariel D, Lamendola C, **Kim SH,\*** Abbasi F, Cardell J, Tomasso V, Mojaddidi H, Grove K, Kushida CA, Reaven GM. Comparison of the Association with Sleep Apnoea of Obesity versus Insulin Resistance. *European Respiratory Journal* 46:1829-32, 2015. \*Participated in the acquisition of data and revision of manuscript.
- 36. **Kim SH**, Silvers A, Viren J, Reaven GM. Relationship between Insulin Sensitivity and Insulin Secretion Rate: Not Necessarily Hyperbolic. *Diabetic Medicine* 33:961-7, 2016.
- 37. Liu A, **Kim SH,\*** Ariel D, Abbasi F, Lamendola C, Cardell J, Xu S, Patel S, Tomasso V, Mojaddidi H, Grove K, Tsao PS, Kushida CA, Reaven GM. Does Enhanced Insulin Sensitivity Improve Sleep

- Measures in Patients with Obstructive Sleep Apnea: a Randomized, Placebo-controlled Pilot Study. *Sleep Medicine* 33:57-60, 2016. \*Participated in the acquisition of data and revision of manuscript.
- 38. Kim MK, Reaven GM, **Kim SH**. Dissecting the Relationship between Obesity and Hyperinsulinemia: Role of Insulin Secretion and Insulin clearance. *Obesity* 25:378-383, 2017.
- 39. Liu A, Abbasi F, **Kim SH,\*** Ariel D, Lamendola C, Cardell J, Xu S, Patel S, Tomasso V, Mojaddidi H, Grove K, Tsao PS, Kushida CA, Reaven GM. Effect of Pioglitazone on Cardiometabolic Risk in Patients with Obstructive Sleep Apnea. *American Journal of Cardiology* 119:1205-10, 2017. \*Participated in the acquisition of data and revision of manuscript.
- 40. Jung CH, Jung SH, Lee B, Rosenberg M, Reaven GM, **Kim SH**. Relationship among Age, Insulin Resistance, and Blood Pressure. *J of American Society of Hypertension* 11:359-365, 2017.
- 41. Sung KC, Ryu S, Sung JW, Kim YB, Won YS, Cho DS, **Kim SH**,\* Liu A. Inflammation in the Prediction of Type 2 Diabetes and Hypertension in Healthy Adults. *Archives of Medical Research* 48:535-545, 2017. \*Participated in analyzing the data and editing of manuscript.
- 42. Jung SH, Jung CH, Reaven GM, **Kim SH**. Adapting to Insulin Resistance in Obesity: Role of insulin secretion and clearance. *Diabetologia* 61:681-687, 2018.
- 43. LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, **Kim SH**, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort that Will Inform Diabetes Prevention Efforts. *Diabetes Care* 41: 1590-1599, 2018. \*Participated in the concept and editing of the manuscript.
- 44. Sung KC, Lee MY, Lee JY, Lee SH, Kim SH. Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. *Journal of Clinical Medicine* 8:E445, 2019.
- 45. Kim DH, Li A, Cholankeril G, **Kim SH**, Ingelsson E, Knowles J, Harrington R, Ahmed A. Trends in overall, cardiovascular, and cancer related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. *Diabetologia* 62:1185-1194, 2019. \*Participated in critical review of manuscript.
- 46. Kim SH, Sung KC, Lee SK, Park J, Kim NH, **Kim SH**, Shin C. Longitudinal changes in left ventricular structure and function in patients with type 2 diabetes: Normal weight versus overweight. *Diabetes and Vascular Disease Research* 16:450-457, 2019. \*Shared last-author with C. Shin.
- 47. Pittas AG, Dawson-Hughes B, Sheehan P, Knowler WC, Aroda VR, Brodsky IG, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, **Kim SH**, LeBlanc, ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M; D2d Research Group. Vitamin D supplementation and prevention of type 2 diabetes. *NEJM* 381: 520-530, 2019. \*Participated in study concept and completion; critical review of manuscript.
- 48. Raygor V, Abbasi F, Lazzeroni L, **Kim SH**, Ingelsson E, Reaven GM, Knowles JW. Impact of race/ethnicity on insulin resistance and hypertriglyceridemia. *Diabetes and Vascular Disease Research* 16:153-159, 2019. \*Participated in critical review of manuscript.
- 49. Kim DH, Cholankeril G, **Kim SH**, Abbasi F, Knowles JW, Ahmed A. Increasing mortality among patients with diabetes and chronic liver disease from 2007 through 2017. *Clinical Gastroenterology and Hepatology* 18:992-994, 2019. \*Participated in critical review of manuscript.

- 50. Rhee JJ, Han J, Montez-Rath M, **Kim SH**, Cullen M, Stafford RS, Winkelmayer WC, Chertow GM. Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. *Journal of Diabetes and Its Complications* 33: 107423, 2019. \*Participated in critical review of manuscript.
- 51. Chang JJ, Lathi R, **Kim SH**. A retrospective study examining phentermine on preconception weight loss and pregnancy outcomes. *Endocrine Practice*, 26:990-996, 2020.
- 52. **Kim SH,** Abbasi, F, Nachmanoff C, Stefanakis, K, Kumar A, Kalra B, Savjani G, Mantzoros C. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: a randomized controlled trial. *Diabetes, Obesity, and Metabolism* 23: 489-98, 2021.
- 53. Kim SW, Lee JS, Lee SK, Abbott R, Lee KY, Lim H, Sung KC, Cho GY, Koh KK, **Kim SH**, Shin C, Kim SH. Association of pericardial adipose tissue with left ventricular structure and function: a region-specific effect? *Cardiovascular Diabetology*, 20:26, 2021. \*Participated in critical review of manuscript.
- 54. Landry MJ, Crimarco A, Perelman D, Durand L, Petlura C, Aronica L, Robinson J, **Kim SH**, Gardner C. Adherence to ketogenic and Mediterranean study diets in a crossover trial: The Keto-Med Randomized Trial. *Nutrients*, 13:967, 2021. \*Participated in study concept, completion, and analysis; critical review of manuscript.
- 55. **Kim SH**, Brodsky IG, Chatterjee R, Kashyap SR, Knowler WC, Liao E, Nelson J, Pratley R, Rasouli N, Vickery EM, Sarnak M, Pittas AG. Effect of Vitamin D supplementation on kidney function in adults with prediabetes: A secondary analysis of a randomized trial. *CJASN*, 16:1201-1209, 2021
- 56. Rasouli N, Brodsky I, Chatterjee R, **Kim SH**, Pratley R, Staten M, Pittas A. Effects of Vitamin supplementation on insulin sensitivity and secretion in pre-diabetes. *JCEM* 107:230-240, 2021 \*Participated in study concept and analysis; critical review of manuscript.
- 57. Abbasi F, Lamendola C, Harris C, Harris V, Tsai M, Tripathi P, Abbas F, Reaven G, Reaven P, Synder M, **Kim SH**, Knowles JW. Statins are associated with increased insulin resistance and secretion. *Arteriosclerosis, Thrombosis, and Vascular Biology* 41:2786-2797, 2021 \*Participated in study concept, completion and analysis; critical review of manuscript.
- 58. Rhee JJ, Han J, Montez-Rath ME, **Kim SH**, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM. Cardiovascular outcomes associated with prescription of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. *Diabetes, Obesity, and Metabolism* 24:928-937, 2022. \*Participated in study concept and analysis; critical review of manuscript.
- 59. Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, Desai M, **Kim SH**, Kwon A. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk non-alcoholic fatty liver disease in primary care. Hepatology 77:356-267, 2022 \*Participated in study concept; critical review of manuscript.
- 60. Gardner C, Landry M, Perelman D, Petlura C, Durand L, Aronica L, Crimarco A, Cunanan K, Chang A, Dant, C, Robinson J, **Kim SH**. Effect of a ketogenic diet versus Mediterranean diet on HbA1c in individuals with prediabetes and type 2 diabetes mellitus: The interventional Keto-Med randomized crossover trial. *American Journal of Clinical Nutrition* 116:640-652, 2022.
- 61. Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-related hyperglycemia. *JCEM* 108:858-864, 2023. \*Participated in study concept and analysis; critical review of manuscript.

### Peer-reviewed Publications (Other)

1. **Kim SH**, Chang TI, Mahaffey KW. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors. *Cardiovascular Therapeutics*, 9:219-225, 2020.

## Non-peer-reviewed Articles

- 1. **Kim SH**, Reaven GM. The Metabolic Syndrome: One Step Forward, Two Steps Back. *Diabetes & Vascular Disease Research* 1:68-75, 2004.
- 2. Kim SH, Reaven GM. Obesity and Insulin Resistance: an Ongoing Saga. Diabetes 59:2105-6, 2010.
- 3. **Kim SH**. Measurement of insulin action: A tribute to Sir Harold Himsworth. *Diabetic Medicine* 28:1487-1493, 2011.
- 4. Sarraju A, **Kim SH**, Knowles JW. Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. *Current Atherosclerosis Reports* 18:7, 2016.
- 5. **Kim SH**, Reaven GM. Insulin clearance: an underappreciated modulator of plasma insulin concentration. *Journal of Investigative Medicine* 64:1162-5, 2016.
- 6. Yu MK, **Kim SH**. Second-line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. *Clinical Journal of American Society of Nephrology* 11:2104-6, 2016.
- 7. **Kim SH**, Reaven GM. Salsalate treatment for prediabetes: a therapeutic alternative? *Diabetic Medicine*, 2016
- 8. **Kim SH,** Abbasi F. Myths about Insulin Resistance: Tribute to Gerald Reaven. *Endocrinology and Metabolism* 34:47-52, 2019.
- 9. **Kim SH**. A Nuanced Relationship between Prediabetes and Chronic Kidney Disease. *Journal of Clinical Endocrinology and Metabolism* 105: e1906-e1907, 2020.

# Abstracts Not Published in Other Forms

- Kim SH, Mealey J, Moore S, Santana-Mora S, Moreno C, Miles P, Du N, Feeley T, Herbert J, Cabaj RP, Louie AK. "Improving metabolic health in patients with severe mental illness." 10<sup>th</sup> Annual Community Health Symposium, Stanford, CA, 2011.
- 2. Tan M, **Kim SH**. "Does polycystic ovarian syndrome increase insulin resistance above and beyond obesity?" American Diabetes Association Annual Meeting, Philadelphia, PA, 2012.
- 3. **Kim SH**, Reaven G. "Statin-induced Glucose Tolerance." American Diabetes Association Annual Meeting, New Orleans, LA, 2016.
- 4. **Kim SH**, Reaven G. "Racial Differences in Insulin Resistance, Secretion, and Clearance." American Diabetes Association Annual Meeting, Orlando, FL, 2018.
- Landry MJ, Aronica L, Crimarco A, Cunanan K, Perelman D, Petlura C, Durand L, A Chang, Robinson J, Kim SH, Gardner C. "Effect of Ketogenic Diet vs Mediterranean Diet on HbA1c: The Keto-Med Randomized Crossover Trial. The Obesity Society, Virtual, 2021

# **Book Chapters**

Lathi RB, **Kim SH**, Comstock I. "Obesity and the endometrium." In Simón and Giudice (Eds.), The Endometrial Factor (pp. 111-119), 2017.

## **Invited Commentaries**

**Kim SH.** "Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients with Type 2 Diabetes." *Practice Update*, November 18, 2019

**Kim SH**. "Nuanced Relationship between Prediabetes and Chronic Kidney Disease." *Journal of Clinical Endocrinology and Metabolism*, 105 (4): e1906-7, 2020

Kim SH. "Nomenclature for Kidney Function and Disease." Practice Update, July 24, 2020

# **INVITED PRESENTATIONS**

Oral Presentations	s: National/International
2004	"Impact of Degree of Obesity on Surrogate Estimates of Insulin Resistance." World
2001	Congress on the Insulin Resistance Syndrome, Los Angeles, CA
2006	"Surrogate Metabolic Markers of Insulin Resistance." Annual World Congress on
2000	the Insulin Resistance Syndrome, San Francisco, CA
2007	"Insulin Resistance and the Many Faces of the Metabolic Syndrome." American
2007	College of Neuropsychopharmacology Annual Meeting, Boca Raton, FL
2008	"Effect of 8 Weeks of Red Wine and Vodka on Insulin Sensitivity in Insulin Resistant
2000	Individuals." American Diabetes Association Annual Meeting, San Francisco, CA
2009	"Plasma Glucose and Insulin Regulation is Abnormal Following Gastric Bypass
2003	Surgery with or without Neuroglycopenia." American Diabetes Association Annual
	Meeting, New Orleans, LA
2010	"Metabolic Complications of Antipsychotic Medications." World Congress on the
2010	Insulin Resistance Syndrome, San Francisco, CA
2010	"Gastric Bypass Surgery and the Story of Hyperinsulinemic Hypoglycemia." GRAND
2010	Annual Meeting, San Francisco, CA
2010	"Glucose-stimulated Insulin Secretion in Gastric Bypass Patients with Hypoglycemic
2010	Syndrome: No Evidence for Inappropriate Pancreatic β-cell Function." American
	Diabetes Association Annual Meeting, Orlando, FL
2011	"Pancreatic β-cell Function after Gastric Bypass: The Story of Hyperinsulinemic
2011	Hypoglycemia." World Congress on the Insulin Resistance Syndrome, Los Angeles,
	CA
2012	"Fork in the Road of Insulin Resistance: Understanding Pancreatic β-Cell Function."
2012	Duke Endocrinology Grand Rounds, Durham, NC
2012	"Glucagon-like Peptide 1 and Pancreatic β-Cell Function." Duke-NUS Research
	Conference, Singapore, Singapore
2014	"Differences in Insulin Resistance and Cardiovascular Risk between Men and
-	Women." World Congress on Insulin Resistance, Diabetes, and Cardiovascular
	Disease, Los Angeles, CA
2015	"Salsalate on Insulin Action, Secretion, and Clearance in Nondiabetic, Insulin-
	Resistant Individuals." American Diabetes Association Annual Meeting, San
	Francisco, CA"GLP-1 Receptor Agonists for the Treatment of Obesity." American
	Diabetes Association Annual Meeting, Boston, MA
2015	"GLP-1 Receptor Agonists for the Treatment of Obesity." UC Davis Endocrine
	Research Conference, Davis, CA
2015	"Insulin Resistance and Amino Acids." World Congress on Insulin Resistance,
	Diabetes, and Cardiovascular Disease, Los Angeles, CA
2016	Session Chair, American Diabetes Association Annual Meeting, New Orleans, LO
2018	"Adapting to Insulin Resistance in Obesity: Role of insulin resistance and insulin
	secretion." World Congress on Insulin Resistance, Diabetes, and Cardiovascular
	Disease, Los Angeles, CA
2022	"Impact of SGLT2 Inhibitors and GLP-1 Agonists on Diabetes, Cardiovascular Disease,
	and Kidney Function." 28th Annual Cardiovascular Nursing Symposium, Las Vegas,
	NV

Regional (Sin	ce 2010)
2010	Community Seminar on Recurrent Pregnancy Loss, Arrillaga Alumni Center,
	Stanford, CA
2010	Stanford University Women's Health Medical Forum, Stanford, CA
2011	Stanford University Endocrinology Grand Rounds, Stanford, CA
2011	Endocrinology Update for Primary Care Practitioners, Li Ka Shing Center, Stanford,
	CA
2011	Obesity in America, Continuing Medical Education Course, Arrillaga Alumni Center, Stanford, CA
2012	Women's Health Forum, Li Ka Shing Center, Stanford, CA
2013	Stanford University Endocrinology Grand Rounds, Stanford, CA
2014	Stanford Parent Weekend, Stanford, CA
2015	Stanford University Nephrology Research Conference, Stanford, CA
2015	Stanford University Endocrinology Grand Rounds, Stanford, CA
2016	Stanford University Endocrinology Grand Rounds, Stanford, CA
2017	"How to Understand the Metabolism." Regional Medical Center.
	"Fatty Liver." 3rd Annual Frontiers in Diabetes Research Symposium, Stanford, CA
2018	"Social Determinants of Type 2 Diabetes." Natividad Medical Center, Salinas, CA
	"Polycystic Ovarian Syndrome." Regional Medical Center, San Jose, CA
2019	"Real-time Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes."
	Stanford Diabetes Research Forum, Stanford, CA
	"Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical
	Evaluation " Stanford Medicine Grand Rounds, Stanford, CA
2020	"Type 2 Diabetes: the Endocrinologist View." Bayer Symposium, Stanford, CA
	"New Medications for T2DM and Clinical Practice Guidelines." Bayer Symposium,
	Stanford, CA
2021	"A New Paradigm in Diabetes Care." Sutter Roseville Medical Center, Roseville, CA
	"Diabetes Debunked: Fact vs fiction." Health Matters, Stanford, CA
	"Metabolic Syndrome." Virtual, Kazakstan.
	"Losing Weight—in Psychiatry." Psychiatry Grand Rounds, Stanford, CA
	"Understanding Obesity: From Stigma to Solutions." Stanford Health Library,
	Stanford, CA
	"New Era in Obesity Management." Stanford Center for Clinical Research, Stanford,
	CA
2022	"Fatty Liver Disease and Obesity." Stanford Liver Education and Awareness
	Program (LEAP), Stanford, CA
	"Type 2 Diabetes in Asian Americans." Stanford Center for Asian Health Research
	and Education (CARE) Charles and CA

and Education (CARE), Stanford, CA